What changed
$GSK — BUY 📊 | 6 MONTHS THESIS
🎯 latest | Rev $1.9B | EPS $1.26 vs $1.16 🟢
💡 Consensus expected flat to down earnings due to patent cliffs and slow vaccine recovery, but the beat reveals resilient specialty and vaccine demand that is not priced in. The market is wrong to value GSK at a trough multiple when fundamentals are improving.
📉 Reward/risk: 2.09:1
🏢 Business Quality: 7/10
📊 Valuation: cheap — forward P/E 10.3x vs. peer 12–15x, EV/EBITDA 7.5x vs. 9–11x, FCF yield 8%. DCF implies fair value $58–62 assuming 2% terminal growth.
🔮 Catalyst: FY2026 guidance raise on next earnings call
💰 Entry: $51.89, stop $48, target $60
⚖️ Buy GSK at $51.89 with a 3-month target of $60 — the EPS beat is a catalyst for multiple repricing from distressed levels.
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/GSK0625